Основная статистика
| CIK | 1722964 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Y-mAbs Therapeutics, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company — Issuer) YOSEMITE MERGER SUB, INC. (Offeror) a wholly owned subsidiary of PERSEUS BIDCO US, INC. (Parent of Offeror) Common Stock, par value $0.0001 per share (Title o |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Y-MABS THERAPEUTICS, INC. (Name of Subject Company) Y-MABS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 |
|
| August 18, 2025 |
Exhibit (e)(7) ADDENDUM TO EMPLOYMENT CONTRACT Between Y-mAbs Therapeutics A/S Agern Allé 11 2970 Hørsholm (the “Employer”) and Joris Wilms (the “Employee”) (collectively the “Parties”) With effect from June 1, 2020, the Employment Contract entered into between the Parties (with previous amendments) shall be amended as follows: 1. |
|
| August 18, 2025 |
Exhibit (a)(1)(ii) Letter of Transmittal to Tender Shares of Common Stock of Y-MABS THERAPEUTICS, INC. |
|
| August 18, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Y-MABS THERAPEUTICS, INC. |
|
| August 18, 2025 |
Table 1: Transaction Valuation Calculation of Filing Fee Tables Table 1: Transaction Valuation Transaction Valuation Fee Rate Amount of Filing Fee Fees to be Paid 1 $ 411,886,943. |
|
| August 18, 2025 |
Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Y-MABS THERAPEUTICS, INC. |
|
| August 18, 2025 |
Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Y-MABS THERAPEUTICS, INC. |
|
| August 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company) Y-MABS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 |
|
| August 18, 2025 |
EMPLOYMENT AGREEMENT for DOUG GENTILCORE Exhibit (e)(8) EMPLOYMENT AGREEMENT for DOUG GENTILCORE This Employment Agreement (the “Agreement”) is made between Y-mAbs Therapeutics, Inc. |
|
| August 18, 2025 |
This Mutual Confidentiality Agreement Exhibit (e)(3) This Mutual Confidentiality Agreement (this “Agreement”), dated as of February 4, 2025, is by and between BTG International Inc, a Delaware corporation (“Serb”), and Y-mAbs Therapeutics, Inc. |
|
| August 18, 2025 |
Exhibit (a)(1)(iii) Notice of Guaranteed Delivery to Tender Shares of Common Stock of Y-MABS THERAPEUTICS, INC. |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company — Issuer) YOSEMITE MERGER SUB, INC. (Offeror) a wholly owned subsidiary of PERSEUS BIDCO US, INC. (Parent of Offeror) Common Stock, par value $0.0001 per share (Title o |
|
| August 18, 2025 |
This Mutual Confidentiality Agreement Exhibit d(iii) This Mutual Confidentiality Agreement (this “Agreement”), dated as of February 4, 2025, is by and between BTG International Inc, a Delaware corporation (“Serb”), and Y-mAbs Therapeutics, Inc. |
|
| August 18, 2025 |
Exhibit (e)(10) Y-MABS THERAPEUTICS, INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION APPROVED BY THE BOARD OF DIRECTORS: January 6, 2025 1. Introduction. The purpose of this Y-mAbs Therapeutics, Inc. Executive Severance Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible executives of the Company whose employment is terminated by the Company or a succe |
|
| August 18, 2025 |
Y-MABS THERAPEUTICS, INC. INVENTION AND CONFIDENTIAL INFORMATION AGREEMENT Exhibit (e)(9) December 19, 2023 JOHN LAROCCA Re: Y-mAbs Therapeutics, Inc. — Offer of Employment Dear John: It is a pleasure to offer you employment with Y-mAbs Therapeutics, Inc. (“the Company”) in the position of General Counsel, Vice President Legal. You will report directly to Chief Executive Officer, Michael Rossi (“the Manager”) or another individual designated by him. You shall perform suc |
|
| August 18, 2025 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mA |
|
| August 8, 2025 |
Exhibit 99.1 Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments ● Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 million ● SERB Pharmaceuticals to acquire Y-mAbs in $412.0 million transaction; transaction expected to close by the fourth quarter of 2025 |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| August 6, 2025 |
Exhibit 99.2: Employee FAQ, dated August 6, 2025. Exhibit 99.2 Y-mAbs Employee FAQ 1. What was announced? · We have entered into an agreement under which SERB Pharmaceuticals has agreed to acquire Y-mAbs Therapeutics in a transaction at an equity value for Y-mAbs of $412 million. · Under the terms of the merger agreement, SERB is obligated to initiate a tender offer to acquire all outstanding shares of Y-mAbs for $8.60 per share in cash. · By com |
|
| August 6, 2025 |
Exhibit 99.1: A message to Company employees from Parent, dated August 6, 2025. Exhibit 99.1 FROM: Vanessa TO: Y-mAbs-All TIMING: Day after Announcement SUBJECT: A Note from SERB Dear Y-mAbs team, On behalf of the entire SERB team, I wanted to take a moment to reach out to introduce myself and express my excitement for this next chapter together. SERB is a specialty pharmaceutical company with a global presence across Europe, the U.S., the Middle East and Australia. Founded i |
|
| August 6, 2025 |
A message to Company employees from SERB Pharmaceuticals, dated August 6, 2025. Exhibit 99.1 FROM: Vanessa TO: Y-mAbs-All TIMING: Day after Announcement SUBJECT: A Note from SERB Dear Y-mAbs team, On behalf of the entire SERB team, I wanted to take a moment to reach out to introduce myself and express my excitement for this next chapter together. SERB is a specialty pharmaceutical company with a global presence across Europe, the U.S., the Middle East and Australia. Founded i |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company) YOSEMITE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of PERSEUS BIDCO US, INC. (Parent of Offeror) Common Stock, Par Value $0.0001 Per Share (Title of C |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company) Y-MABS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number of |
|
| August 5, 2025 |
Joint Press Release issued by SERB Pharmaceuticals and the Company, dated August 5, 2025. Exhibit 99.1 FOR IMMEDIATE RELEASE SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Sh |
|
| August 5, 2025 |
Exhibit 99.6: LinkedIn Post, dated August 5, 2025. Exhibit 99.6 Y-mAbs LinkedIn Post Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Y-mAbs and Serb, including statements relating to the ability to complete and the timing of completion of the transactions contemplated by the Agreement and Plan of Merger dated as of August |
|
| August 5, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Acquisition to Include DANYELZA®(Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-mAbs Closing Sha |
|
| August 5, 2025 |
Exhibit 99.2 Y-mAbs Employee Email Sender: Mike Rossi Subject: Important Update on the Next Step in Our Y-mAbs Journey Send Date: August 5, 2025 Distribution: All Employees Y-mAbs Team, Since day one, our mission at Y-mAbs Therapeutics has been clear: bring important new therapies to patients as quickly as possible. Through DANYELZA®, our company has brought one of the most important innovations i |
|
| August 5, 2025 |
Exhibit 99.5: Vendor/Supplier Letter, dated August 5, 2025. Exhibit 99.5 Y-mAbs Vendor / Supplier Courtesy Letter Dear Valued Partner, I am reaching out with important news about Y-mAbs Therapeutics. Today, we announced that we have entered into a definitive agreement under which SERB Pharmaceuticals has agreed to acquire Y-mAbs. Since our founding, patients have been the top priority for Y-mAbs. We recognize that our work with patients is critical as we f |
|
| August 5, 2025 |
Exhibit 10.1 TENDER AND SUPPORT AGREEMENT THIS TENDER AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of August 4, 2025, by and between Perseus BidCo US, Inc., a Delaware corporation (“Parent”), and the undersigned holder (the “Stockholder”) of shares of common stock of Y-mAbs Therapeutics, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein and not def |
|
| August 5, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics Acquisition to Include Naxitamab-gqgk DANYELZA®(Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio Transaction Expands SERB’s Investment in the U.S. SERB to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Y-mAbs for $8.60 Per Share Represents 105% Premium to Y-m |
|
| August 5, 2025 |
Exhibit 99.4: Patient and Patient Advocacy Organization Letter, dated August 5, 2025. Exhibit 99.4 Y-mAbs Patient and Patient Advocacy Organizations Courtesy Letter Hello, I am reaching out with important news about Y-mAbs Therapeutics. Today, we announced that we have entered into a definitive agreement under which SERB Pharmaceuticals has agreed to acquire Y-mAbs. Since our founding, patients have been the top priority for Y-mAbs. We recognize that our work with patients is criti |
|
| August 5, 2025 |
Exhibit 99.3 Specialty pharma SERB to buy Y-mAbs in $412M all-cash deal Endpoints 5 August 2025 By Kyle LaHucik Specialty drugmaker SERB Pharmaceuticals plans to buy cancer biotech Y-mAbs Therapeutics to further broaden its portfolio of more than 70 medicines. SERB will pay $8.60 per share to buy Y-mAbs $YMAB, the companies said Tuesday morning. Y-mAbs’ stock price skyrocketed 103% to $8.51 apiece |
|
| August 5, 2025 |
Exhibit 99.2 |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 Y-mAbs Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38650 47-4619612 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 5, 2025 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER among: Perseus BidCo US, Inc., a Delaware corporation; Yosemite Merger Sub, Inc., a Delaware corporation; Y-mAbs Therapeutics, Inc., a Delaware corporation; and solely for the purposes of Section 5.16 and Article 8 Stark International Lux, a Luxembourg société à responsabilité limitée Dated as of August 4, 2025 TABLE OF CONTENTS Page Art |
|
| August 5, 2025 |
Exhibit 99.3: Investor/Analyst Letter, dated August 5, 2025. Exhibit 99.3 Y-mAbs Investor / Analyst Courtesy Letter Subject: Y-mAbs Agrees to be Acquired by SERB for $8.60 per Share Good morning, I’m pleased to share that Y-mAbs Therapeutics has entered into a definitive agreement under which SERB Pharmaceuticals has agreed to acquire Y-mAbs in a transaction with an equity value of $412 million. Members of the management team will be available to answer que |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company) YOSEMITE MERGER SUB, INC. (Offeror) A Wholly Owned Subsidiary of PERSEUS BIDCO US, INC. (Parent of Offeror) Common Stock, Par Value $0.0001 Per Share (Title of C |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Y-MABS THERAPEUTICS, INC. (Name of Subject Company) Y-MABS THERAPEUTICS, INC. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number of |
|
| July 15, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 11, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| May 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin |
|
| May 28, 2025 |
Radiopharmaceutical R&D Update May 28, 2025 Exhibit 99.1 Radiopharmaceutical R&D Update May 28, 2025 Disclaimer Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995 . The forward - looking statements involve substantial risks and uncertainties . All statements, other than statements of historical facts, contained in this presentatio |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 28, 2025 |
Exhibit 99.2 Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - Company’s Part A data readout from first-in-human Phase 1 Trial 1001 in patients with recurrent or refractory metastatic solid tumors known to express GD2, validates GD2-SADA as safe, tolerable and able to achieve targeted in vivo conjugation of 177Lu-DOTA - Increas |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-m |
|
| May 13, 2025 |
Exhibit 99.1 Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments ● Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% ● National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA®) ● Dosed first patient |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One) ☒Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. for the transition period from to . Commission File Number 001- |
|
| April 29, 2025 |
Amended and Restated Non-Employee Director Compensation Policy, effective March 18, 2025. Exhibit 10.44 Y-MABS THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (the “Policy”), which establishes compensation to be paid to Non-Employee Directors (as defined below) of the Company, as an |
|
| March 4, 2025 |
Up to $35,000,000 Common Stock 424B5 1 tmb-20250304x424b5.htm 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-271006 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 5, 2023) Up to $35,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Distribution Agreement, dated as of March 4, 2025, with Oppenheimer & Co. Inc., or the Sales Agent, relating to the sale of shares o |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| March 4, 2025 |
Exhibit 10.43 First Amendment to the LICENSE AGREEMENT Between Y-mAbs Therapeutics, Inc. and SciClone Pharmaceuticals International Ltd. This First Amendment to the License Agreement (the “Amendment”) is entered into as of December 9, 2024 (the “Effective Date”), by and between Y-mAbs Therapeutics, Inc., a Delaware corporation with its principal offices located at 230 Park Avenue, Suite 3350, New |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 4, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| March 4, 2025 |
Exhibit 10.42 MENDMENT NO. 3 AMENDMENT NO. 3 to LICENSE AGREEMENT DATED August 20, 2015 between MEMORIAL SLOAN-KETTERING CANCER CENTER and Y-MABS THERAPEUTICS, INC. i Amendment no. 3 to license agreement This Amendment No. 3 (“Amendment”), effective on the date of the last signature below (“Amendment Effective Date”), is made to that certain License Agreement dated August 20. 2015, as amended on M |
|
| March 4, 2025 |
Y-mAbs Therapeutics, Inc. Insider Trading Compliance Policy Exhibit 19.1 Y-mAbs Therapeutics, Inc. Insider Trading Compliance Policy I. PURPOSE Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) has adopted this Insider Trading Compliance Policy (the “Policy”) to assist with compliance with insider trading laws and to prevent even the appearance of improper trading. Additionally, this Policy prohibits the unauthorized disclosure and misuse of any materi |
|
| March 4, 2025 |
Exhibit 21.1 Subsidiary of the Registrant Y-mAbs Therapeutics A/S (Denmark) |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38 |
|
| March 4, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Y-mAbs Therapeutics, Inc. |
|
| March 4, 2025 |
Exhibit 99.1 Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total Revenues of $26.5 million for the fourth quarter of 2024 and $87.7 million for the full year 2024 ● The Company established two business units in January 2025 aimed to accelerate the clinical development of its Radiopharmaceuticals Platform and optimize the commercial potential of D |
|
| March 4, 2025 |
Exhibit 1.1 Y-MABS THERAPEUTICS, INC. EQUITY DISTRIBUTION AGREEMENT March 4, 2025 Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, New York 10004 Ladies and Gentlemen: Y-mAbs Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, |
|
| March 4, 2025 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 25, 2025, Y-mAbs Therapeutics, Inc. (“Y-mAbs,” “we,” “our” or “us”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share. The followin |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| January 10, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| January 10, 2025 |
Exhibit 99.1 Y-mAbs Provides Strategic Business Update and 2025 Priorities Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expec |
|
| November 14, 2024 |
YMAB / Y-mAbs Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this stateme |
|
| November 8, 2024 |
Exhibit 10.4 LICENSE AGREEMENT LICENSE AGREEMENT, dated as of September 11, 2024, between Princeton 202 Associates Limited Partnership, a New Jersey limited partnership, with offices c/o Boston Properties at 101 Carnegie Center, Suite 104, Princeton, New Jersey 08540 (the “Licensor”), and Y-mAbs Therapeutics, Inc., a Delaware corporation, with its principal office at 230 Park Avenue, Suite 3350, N |
|
| November 8, 2024 |
Exhibit 99.1 Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024 ● Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing an upfront payment of $2.0 million in the fourth quarter of 2024 ● Achieved extension of primary |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 |
|
| November 8, 2024 |
Exhibit 10.3 LEASE AND LEASE AGREEMENT Between Princeton 202 Associates Limited Partnership The Landlord And Y-mAbs Therapeutics, Inc. The Tenant For Leased Premises In 202 Carnegie Center Princeton, New Jersey September 11, 2024 Prepared by: Gregory S. Ricciardi, Esq. Boston Properties 101 Carnegie Center, Suite 104 Princeton, New Jersey 08540 TABLE OF CONTENTS Page 1 Definitions1 2 Lease of th |
|
| November 4, 2024 |
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA Exhibit 99.1 Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan New York, NY and Japan, November 4, 2024 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic prod |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 4, 2024 |
Exhibit 10.1 Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. LICENSE AGREEMENT This License Agreement (this “Agreement”) is made and entered into as of October 23, 2024 (the “Effective Date”) by and between: Y-mAbs Therapeutics, Inc. (“Licensor”), a corporation |
|
| November 4, 2024 |
YMAB / Y-mAbs Therapeutics, Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 UnitedStates13GY-mAbsTher.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* (Name of Issuer) Y-mAbs Therapeutics Inc (Title of Class of S |
|
| September 26, 2024 |
September 26, 2024 United States Securities and Exchange Commission Division of Corporate Finance Office of Life Sciences Washington, D. |
|
| September 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or orga |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or orga |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| August 12, 2024 |
Exhibit 99.1 Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments ● Reported Total DANYELZA net product revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase ● Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong ● Part A of |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mA |
|
| July 19, 2024 |
Exhibit 10.1 15th July 2024 SEPARATION AGREEMENT BETWEEN Y-mAbs Therapeutics A/S (CVR no. 37053678) Agern Alle 11 2970 Hørsholm ("Company") AND Bo Kruse Ängavångsvägen 4 S-21851 Klagshamn Sverige (SE) ("BK” ) (jointly the "Parties" or individually the “Party”) 1. Termination of employment 1.1 Effective as of 1 October 2015, BK was employed by the Company as CFO on the terms and conditions set out |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 16, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| July 19, 2024 |
Exhibit 10.2 Consultancy agreement This consultancy agreement (the “Agreement”) has been made by and between: 1. Y-mAbs Therapeutics, Inc., a company limited by shares incorporated in the United States under corporate registration number 47-4619612 (the “Company”), with registered address at 230 Park Avenue, Suite 3350 New York, NY 10169, USA; and 2. Investeringsselskabet GH ApS, a company limited |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| July 1, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT for PETER PFREUNDSCHUH This Employment Agreement (the “Agreement”) is made this 28th June, 2024 between Y-mAbs Therapeutics, Inc. (the “Company”) and Peter Pfreundschuh (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company as well as its subsidiaries (together with the Company, the “Group”), |
|
| July 1, 2024 |
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer Exhibit 99.1 Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer New York, NY, July 1, 2024 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 26, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| June 13, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-m |
|
| May 7, 2024 |
Exhibit 99.1 Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments ● Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% ● Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumes ● Cash and c |
|
| May 7, 2024 |
Exhibit 10.3 The following severance agreement (the “Agreement”) has been entered into by Y-mAbs Therapeutics A/S CVR No. 37053678 Agern Allé 11 DK – 2970 Hørsholm (hereinafter the “Company”) and Steen Lisby Vibevang 2 DK – 2970 Hørsholm (hereinafter the “Employee”) (The Company and the Employee each a “Party” and together the “Parties”) SEVERANCE AGREEMENT 1. BACKGROUND 1.1 The Employee has been |
|
| May 7, 2024 |
Exhibit 10.4 Y-MABS THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (the “Policy”), which establishes compensation to be paid to Non-Employee Directors (as defined below) of the Company, as an i |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizatio |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin |
|
| April 29, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| April 8, 2024 |
YMAB / Y-mAbs Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) March 27, 2024 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the |
|
| April 8, 2024 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| March 14, 2024 |
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer Exhibit 99.1 Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer New York, NY, March 14, 2024 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Chief |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 8, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| March 4, 2024 |
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors Exhibit 99.1 Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors Dr. Tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development New York, NY, March 4, 2024 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| February 29, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Y-mAbs Therapeutics, Inc. |
|
| February 29, 2024 |
Y-mAbs Therapeutics, Inc. Executive Compensation Recoupment Policy (filed herewith) Exhibit 97.1 Y-MABS THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1.INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy |
|
| February 29, 2024 |
EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 22, 2024, Y-mAbs Therapeutics, Inc. (“Y-mAbs,” “we,” “our” or “us”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share. The followin |
|
| February 29, 2024 |
Exhibit 10.46 Y-MABS THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN PERRFORMANCE-BASED RESTRICTED STOCK UNIT AWARD GRANT NOTICE Y-mAbs Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2018 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of performance-based restricted stock units (“P |
|
| February 29, 2024 |
Exhibit 21.1 Subsidiary of the Registrant Y-mAbs Therapeutics A/S (Denmark) |
|
| February 29, 2024 |
Exhibit 10.34 EMPLOYMENT AGREEMENT for Vignesh Rajah This Employment Agreement (the “Agreement”) is made between Y-mAbs Therapeutics, Inc. (the “Company”) and Vignesh Rajah (the “Executive”) (collectively, the “Parties”). WHEREAS, the Company desires for Executive to provide services to the Company as well as its subsidiaries (together with the Company, the “Group”), and wishes to provide Executiv |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38 |
|
| February 29, 2024 |
As filed with the Securities and Exchange Commission on February 29, 2024 As filed with the Securities and Exchange Commission on February 29, 2024 Registration No. |
|
| February 29, 2024 |
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments Exhibit 99.1 Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments · Record DANYELZA® net product revenues of $23.4 million and $84.3 million for Q4 and FY 2023 represents YoY growth of 42% and 71%, respectively · Cash and cash equivalents of $78.6 million as of December 31, 2023; Reiterate anticipated cash runway into 2027 · Management announces full |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| February 14, 2024 |
Joint Filing Agreement, dated as of February 14, 2024 EX-99.1 2 tm246115d1ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement (the “Agreement”) is made and entered into as of February 14, 2024, by and among WG Biotech ApS and Johan Wedell-Wedellsborg (collectively referred to herein as the “Filers”). Pursuant to and in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the Filers hereby agr |
|
| February 14, 2024 |
YMAB / Y-mAbs Therapeutics, Inc. / WG Biotech ApS - SC 13G/A Passive Investment SC 13G/A 1 tm246115d1sc13g.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 13, 2024 |
YMAB / Y-mAbs Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02324-ymabstherapeuticsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Y-mAbs Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 984241109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| February 13, 2024 |
SC 13G/A 1 tm245871d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement |
|
| February 6, 2024 |
SC 13G/A 1 p24-0355sc13ga.htm Y-MABS THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statem |
|
| January 9, 2024 |
Exhibit 99.1 Oncology Leadership in Pretargeted Radioimmunotherapy Platform and Antibody - based Therapies January 2024 Disclaimer Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 a |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2024 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| November 13, 2023 |
Exhibit 99.1 Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments · Q3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59% · U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin Lymphoma · Cash and cash equivalents of $86.6 million as of September 30, 2023, with anticipated cash runway extended into 2027 · Man |
|
| November 13, 2023 |
Exhibit 10.1 AMENDMENT TO LEASE This AMENDMENT TO LEASE (this “Amendment”) dated as of August 16th, 2023 (the “Effective Date”) between RXR HB OWNER LLC, having an office c/o RXR Realty LLC, 625 RXR Plaza, Uniondale, New York 11556 (“Landlord”), and Y-MABS THERAPEUTICS, INC., having an office at 230 Park Avenue, New York, New York 10169 (“Tenant”). W I T N E S E T H: WHEREAS, Landlord and Tenant e |
|
| October 18, 2023 |
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director Exhibit 99.1 Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director New York, NY, October 18, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced today th |
|
| October 18, 2023 |
Exhibit 10.2 Y-MABS THERAPEUTICS, INC. EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT In consideration of my employment or continued employment by Y-mAbs Therapeutics, Inc. (“Employer”), and its subsidiaries, parents, affiliates, successors, and assigns (together with Employer, “Company”), the compensation paid to me now and during my employment with Company, and Company’s a |
|
| October 18, 2023 |
Exhibit 99.1 Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA Clearance of CD38-SADA IND marks the second clinical development program utilizing the Company’s novel SADA technology platform New York, NY, October 17, 2023 – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused o |
|
| October 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 17, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| October 18, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT for MICHAEL ROSSI This Employment Agreement (the “Agreement”) is made between Y-mAbs Therapeutics, Inc. (the “Company”) and Michael Rossi (the “Executive”) (collectively, the “Parties”). Whereas, the Company desires for Executive to provide services to the Company as well as its subsidiaries (together with the Company, the “Group”), and wishes to provide Executive |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| August 10, 2023 |
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments Exhibit 99.1 Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments · Q2 2023 DANYELZA® record net product revenues of $20.8 million, driving YoY growth of 112% and a 3% sequential increase compared to Q1 2023 · Management reiterates FY 2023 financial guidance · DANYELZA marketing authorization granted in Brazil · Ongoing patient recruitment in the Phase I GD2-SADA |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-mA |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 26, 2023 |
Y-mAbs Announces Presentation of Naxitamab Data at ASCO Exhibit 99.1 Y-mAbs Announces Presentation of Naxitamab Data at ASCO New York, NY, May 26, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation feat |
|
| May 26, 2023 |
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO Exhibit 99.2 Y-mAbs Announces Presentation of GD2-SADA Study at ASCO New York, NY, May 26, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation feat |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 23, 2023 |
Exhibit 99.1 Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil New York, NY, May 23, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, toda |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizatio |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38650 Y-m |
|
| May 8, 2023 |
Exhibit 99.1 Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance ● Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 ● Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cas |
|
| May 2, 2023 |
Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York, NY 10169 Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350 New York, NY 10169 May 2, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Y-mAbs Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-271006) Request for Acceleration of Effective Date Mr. Crawford: In accordance with Rule 4 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by R |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 18, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| April 18, 2023 |
Y-mAbs Announces Presentation of Naxitamab data at AACR Exhibit 99.1 Y-mAbs Announces Presentation of Naxitamab data at AACR New York, NY, April 18, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a poster presentation fe |
|
| April 5, 2023 |
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA Exhibit 99.1 Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA New York, NY, April 5, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the fi |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| April 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) March 15, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| March 30, 2023 |
EXHIBIT 10.41 Y-MABS THERAPEUTICS, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors (the “Board”) of Y-mAbs Therapeutics, Inc. (the “Company”) has approved the following Amended and Restated Non-Employee Director Compensation Policy (the “Policy”), which establishes compensation to be paid to Non-Employee Directors (as defined below) of the Company, as an |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38 |
|
| March 30, 2023 |
EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 23, 2023, Y-mAbs Therapeutics, Inc. (“Y-mAbs,” “we,” “our” or “us”), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.0001 per share. The following s |
|
| March 30, 2023 |
Exhibit 99.1 Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments ● Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31% sequential increase compared to Q3 2022 ● DANYELZA conditional marketing authorization granted in China ● Management reiterates 2023 financial guidance ● First ever SADA Phase I trial op |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Y-mAbs Therapeutics, Inc. |
|
| March 30, 2023 |
Subsidiaries of the Registrant EX-21.1 5 ymab-20221231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Y-mAbs Therapeutics A/S (Denmark) Y-mAbs Therapeutics (Cayman Islands) Y-mAbs Therapeutics Limited (United Kingdom) Note: Y-mAbs Therapeutics (Cayman Islands) and Y-mAbs Therapeutics Limited (United Kingdom) are dormant entities without any operations and holding no assets. |
|
| March 30, 2023 |
Employment Agreement for Ms. Susan Smith, effective as of January 1, 2022 (filed herewith). Exhibit 10.42 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this [xx] day of December 2021 (the “Effective Date”), between SUE SMITH, whose principal residence is located at [***](the “Employee”), and Y-MABS THERAPEUTICS, INC., with its principal place of business located at 230 Park Avenue, Suite 3350, New York, New York 10169 (the “Company”) (the Employee and t |
|
| March 30, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 30, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| March 30, 2023 |
Form of Indenture, between the Registrant and one or more trustees to be named Exhibit 4.10 Y-mAbs Therapeutics, Inc. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 S |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Y-mAbs Therapeutics, Inc. |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 Table of Contents As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| February 14, 2023 |
YMAB / Y-mAbs Therapeutics, Inc / WG Biotech ApS - SC 13G Passive Investment SC 13G 1 tm236789d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 14, 2023 |
SC 13G/A 1 tm235913d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2023 |
EX-99.1 2 tm236789d1ex99-1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement (the “Agreement”) is made and entered into as of February 14, 2023, by and among WG Biotech ApS and Johan Wedell-Wedellsborg (collectively referred to herein as the “Filers”). Pursuant to and in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the Filers hereby |
|
| February 9, 2023 |
YMAB / Y-mAbs Therapeutics, Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Y-mAbs Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 984241109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| February 2, 2023 |
Exhibit 99.1 Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab New York, NY, February 2, 2023 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of |
|
| January 4, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2023 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| January 4, 2023 |
Exhibit 99.1 Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA ? Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million; ? Estimated total cash burn for 2023, including restructuring expenses, expected to be $50-55 million, expected to extend cash runway into Q |
|
| December 21, 2022 |
Y-mAbs Announces Partnership regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe Exhibit 99.1 Y-mAbs Announces Partnership regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe New York, NY, December 21, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| December 16, 2022 |
Exhibit 99.1 The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe NEW YORK, December 16, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the |
|
| December 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| December 14, 2022 |
Y-mAbs Announces Pipeline Update Exhibit 99.1 Y-mAbs Announces Pipeline Update New York, NY, December 14, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update for naxitamab and the Comp |
|
| December 8, 2022 |
Exhibit 99.1 Y-mAbs? DANYELZA? (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in China New York, NY, December 8, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, t |
|
| December 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 8, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| December 2, 2022 |
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application Exhibit 99.1 Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application New York, NY, December 1, 2022 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announ |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 1, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2022 |
Form of Stock Option Grant Notice and Stock Option Agreement under the 2018 Equity Incentive Plan. Exhibit 10.1 Y-MABS THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Y-mAbs Therapeutics, Inc. a Delaware corporation, (the ?Company?), pursuant to its 2018 Equity Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s Common Stock (the ?Shares?), |
|
| November 7, 2022 |
Exhibit 10.3 SEPARATION AGREEMENT AND GENERAL RELEASE ? This Separation Agreement and General Release (the ?Agreement?) is made and entered into by and between Y-mAbs Therapeutics, Inc. (the ?Company?), located at 230 Park Avenue, Suite 3350, New York, NY 10169, and its employee, Claus Juan M?ller San Pedro (?Employee?), who resides at [***]. ? WHEREAS, Employee has been employed by the Company as |
|
| November 7, 2022 |
Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands, except share data) Exhibit 99.1 Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments · Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 · DANYELZA marketing authorization granted in Israel; regulatory filing submitted in Brazil · Management reiterates financial guidance, including anticipated 2022 full-year |
|
| November 7, 2022 |
Exhibit 10.2 Y-MABS THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Y-mAbs Therapeutics, Inc. a Delaware corporation, (the ?Company?), pursuant to its 2018 Equity Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (?Participant?), an option to purchase the number of shares of the Company?s Common Stock (the ?Shares?), |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 28, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| October 28, 2022 |
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab Exhibit 99.1 Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab New York, NY, October 28, 2022 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the outcom |
|
| October 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 3, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| October 3, 2022 |
Y-mAbs Announces Pivotal Data for Omburtamab Exhibit 99.1 Y-mAbs Announces Pivotal Data for Omburtamab New York, NY, October 3, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced clinical data on the Company?s product |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 22, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or orga |
|
| September 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or orga |
|
| September 26, 2022 |
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil Exhibit 99.1 Y-mAbs Announces Regulatory Filing for DANYELZA? (naxitamab-gqgk) in Brazil New York, NY, September 26, 2022 (GLOBE NEWSWIRE) ?Y-mAbs Therapeutics, Inc. (?Y-mAbs?, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Adium Pharma S.A. |
|
| September 2, 2022 |
Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab Exhibit 99.1 Y-mAbs Announces Scheduling of FDA Advisory Committee Meeting for Omburtamab New York, NY, September 1, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that |
|
| September 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 2, 2022 (September 1, 2022) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of in |
|
| August 30, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 30, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiz |
|
| August 30, 2022 |
Exhibit 99.1 Y-mAbs and Takeda Announces Marketing Authorization in Israel for DANYELZA® (naxitamab-gqgk) for Neuroblastoma New York, NY, and PETAH TIKVA, Israel, August 30, 2022 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic pr |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 8, 2022 |
Exhibit 10.1 Y-MABS THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Y-mAbs Therapeutics, Inc. a Delaware corporation, (the “Company”), pursuant to its 2018 Equity Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common Stock (the “Shares”), |
|
| August 8, 2022 |
? Exhibit 10.2 ? May 30, 2022 VIA EMAIL Bo Kruse ? ? Re: Retention Bonus ? Dear Bo We are pleased to inform you that, in recognition of your contributions to Y-mAbs Therapeutics A/S (the ?Company?), you are being offered the opportunity to receive a retention bonus (the ?Retention Bonus?) on the following terms and conditions: 1. Payment of Retention Bonus. Subject to satisfaction of the condition |
|
| August 8, 2022 |
Exhibit 10.3 [ ] VIA EMAIL [ ] Re: Retention Bonus Dear [ ] We are pleased to inform you that, in recognition of your contributions to Y-mAbs Therapeutics A/S (the “Company”), you are being offered the opportunity to receive a retention bonus (the “Retention Bonus”) on the following terms and conditions: 1. Payment of Retention Bonus. Subject to satisfaction of the conditions set forth below, you |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organiza |
|
| August 8, 2022 |
Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands, except share data) Exhibit 99.1 Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments ? Omburtamab BLA Accepted by the FDA with November 2022 PDUFA date ? Announced IND Clearance for the first GD2-SADA construct ? YTD DANYELZA? product revenue $20.3 million ? Management reiterates financial guidance, including 2022 full-year DANYELZA? revenue of $45-$50 million ? Strong cash position wi |
|
| August 8, 2022 |
? EXHIBIT 10.4 ? [ ]VIA EMAIL [ ] ? Re: Retention Bonus ? Dear [ ] We are pleased to inform you that, in recognition of your contributions to Y-mAbs Therapeutics, Inc. (the ?Company?), you are being offered the opportunity to receive a retention bonus (the ?Retention Bonus?) on the following terms and conditions: 1. Payment of Retention Bonus. Subject to satisfaction of the conditions set forth be |
|
| July 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| July 12, 2022 |
Y-mAbs’ Announces Clearance of IND for GD2-SADA Exhibit 99.1 Y-mAbs? Announces Clearance of IND for GD2-SADA New York, NY, July 12, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced initiation of its first clinical trial |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2022 (June 9, 2022) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporati |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2022 (May 30, 2022) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporatio |
|
| May 31, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 31, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 31, 2022 |
Exhibit 99.1 Y-mAbs Announces FDA Acceptance of Biologics License Application for OMBLASTYS® (omburtamab) for the Treatment of Neuroblastoma for Priority Review New York, NY, May 31, 2022 (GLOBE NEWSWIRE) – Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based thera |
|
| May 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizati |
|
| May 26, 2022 |
Exhibit 99.1 Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint New York, NY, May 26, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treat |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2022 (May 18, 2022) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporatio |
|
| May 9, 2022 |
? Exhibit 10.9 ? ADDENDUM TO EMPLOYMENT CONTRACT ? Between ? Y-mAbs Therapeutics A/S Agern Alle 11 2970 H?rsholm (the "Employer") and Steen Lisby [***] ? (the "Employee") ? (collectively the "Parties") ? With effect from June 1, 2020, the Employment Contract entered into between the Parties (with previous amendments, the "Employment Contract") shall be amended as follows: ? 1. New Position/Work Re |
|
| May 9, 2022 |
Exhibit 10.11 ADDENDUM TO EMPLOYMENT CONTRACT Between Y-mAbs Therapeutics A/S Agern All? 11 2970 H?rsholm (the ?Employer") and ? Vignesh Rajah (the ?Employee?) (collectively the ?Parties") With effect from March 10, 2021, the Employment Contract entered into between the Parties (with previous amendments, the ?Employment Contract?) shall be amended as follows: ? 1. Additional Clause (take-over prot |
|
| May 9, 2022 |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| May 9, 2022 |
Exhibit 10.10 EMPLOYMENT CONTRACT Between Y-mAbs Therapeutics A/5 Agern Alle 11 2970 H?rsholm (the "Employer") and Dr. Vignesh Rajah? [***] (the "Employee") (collectively the "Parties") 1. Period of employment, Title, Reporting Person 1.1 The Employee is employed as of June 2nd, 2020 by the Employer, a company engaged in drug development. 1.2 The Employee is employed as Senior Vice President and C |
|
| May 9, 2022 |
Exhibit 10.8 EMPLOYMENT CONTRACT Between Y-mAbs Therapeutics A/S Rungsted Strandvej 113 2960 Rungsted Kyst (hereinafter referred to as "the Employer ") and Steen Lisby [***] (hereinafter referred to as "the Employee") (hereinafter collectively referred to as "the Parties") have today entered into the following EMPLOYMENT CONTRACT 1. Period of employment 1.1 The Employee is employed as of August 1s |
|
| May 9, 2022 |
Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands, except share data) Exhibit 99.1 Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments ? Completed resubmission to the FDA of omburtamab BLA ? DANYELZA? adoption drove a 9% sequential revenue increase to $10.5 million ? Company issues 2022 full-year DANYELZA? revenue guidance of $45-$50 million ? Strong cash position with $156.7 million as of March 31, 2022, providing runway through mid-2 |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizatio |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by |
|
| April 27, 2022 |
Exhibit 99.1 Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update ? CEO and Board Member Dr. Claus Moller has stepped down; Thomas Gad, Founder, Chairman and President assumes Interim CEO role and steps down as Chairman; Dr. Jim Healy to be appointed as Chairman ? DANYELZA? first quarter revenues were $10.5 million, up 9% sequentially quarter over q |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2022 (April 22, 2022) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorpor |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 984241109 (CUSIP Number) March 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 1, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organizat |
|
| April 1, 2022 |
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA Exhibit 99.1 Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA New York, NY, April 1, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that on |
|
| March 1, 2022 |
EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 22, 2022, Y-mAbs Therapeutics, Inc. (?Y-mAbs,? ?we,? ?our? or ?us?), had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, par value $0.0001 per share. The followin |
|
| March 1, 2022 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant Y-mAbs Therapeutics A/S (Denmark) ? Y-mAbs Therapeutics (Cayman Islands) ? Y-mAbs Therapeutics Limited (United Kingdom) ? Note: Y-mAbs Therapeutics (Cayman Islands) and Y-mAbs Therapeutics Limited (United Kingdom) are dormant entities without any operations and holding no assets. |
|
| March 1, 2022 |
l UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents l ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| February 25, 2022 |
Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands, except share data) EX-99.1 2 tm227665d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments · Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 · DANYELZA® adoption drives sequential revenue increase · Completed IND submission to the FDA for first SADA cons |
|
| February 15, 2022 |
YMAB / Y-mAbs Therapeutics, Inc / Sofinnova Venture Partners X, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 984241109 (CUSIP Number) Nathalie Auber Sofinnova Investments |
|
| February 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2022 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| February 11, 2022 |
Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab Exhibit 99.1 Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab New York, NY, February 11, 2022 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it rec |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2021 & January 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Y-mAbs Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 984241109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 16, 2021 (December 14, 2021) Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of in |
|
| December 15, 2021 |
Y-mAbs Announces Pipeline Update Exhibit 99.1 Y-mAbs Announces Pipeline Update New York, NY, December 15, 2021 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for naxitamab and data f |
|
| December 15, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2021 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 22, 2021 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organ |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 4, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2021 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organi |
|
| November 4, 2021 |
Exhibit 99.1 Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis New York, NY, November 4, 2021 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treat |
|
| November 4, 2021 |
Y-MABS THERAPEUTICS, INC. Consolidated Balance Sheets (in thousands, except share data) Exhibit 99.1 Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments New York, NY, November 4, 2021 (GLOBE NEWSWIRE) ? Y-mAbs Therapeutics, Inc. (the ?Company? or ?Y-mAbs?) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported f |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
